OQROGet OQRO Pro
Insider trade

Serina Therapeutics (SER)Chief Scientific Officer sold ~$23K

Randall Moreadith, Chief Scientific Officer at Serina Therapeutics, sold ~$23K of Serina Therapeutics shares.

~$23K
Approx. value · 6,500 sh @ $3.57
Traded
Jan 28, 2026
Filed
Jan 29, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 2, 2025InsiderOfficer sold ~$5.9K of SER shares in the open market
  2. Dec 3, 2025InsiderOfficer sold ~$18K of SER shares in the open market
  3. Dec 9, 2025InsiderOfficer sold ~$2K of SER shares in the open market
  4. Dec 10, 2025InsiderOfficer sold ~$2.2K of SER shares in the open market
  5. Dec 11, 2025InsiderOfficer sold ~$12K of SER shares in the open market
  6. Dec 12, 2025InsiderOfficer sold ~$5.5K of SER shares in the open market
  7. Dec 16, 2025InsiderOfficer sold ~$9.6K of SER shares in the open market
  8. Dec 22, 2025InsiderOfficer sold ~$15K of SER shares in the open market
  9. Dec 23, 2025InsiderOfficer sold ~$11K of SER shares in the open market
  10. Jan 9, 2026Company filing · Form 8-K · Listing notice, Reg FDReceived a notice from its stock exchange, and shared information with investors“On January 9, 2026, Serina Therapeutics, Inc. (the “Company”) received a notification (the “Letter”) from The NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of (i) $2.0 million or more if…”
  11. Jan 13, 2026InsiderOfficer sold ~$14K of SER shares in the open market
  12. Jan 14, 2026InsiderOfficer sold ~$2.7K of SER shares in the open market
  13. Jan 20, 2026InsiderOfficer sold ~$6.1K of SER shares in the open market
  14. Jan 21, 2026InsiderOfficer sold ~$6K of SER shares in the open market
  15. Jan 22, 2026InsiderOfficer sold ~$7.4K of SER shares in the open market
  16. Jan 28, 2026 · this disclosureInsiderOfficer sold ~$23K of SER shares in the open market

What came next

  1. Feb 2, 2026InsiderOfficer sold ~$20K of SER shares in the open market
  2. Mar 17, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesChanged a top executive or board member, and signed an important agreement (and 3 more items)“In connection with the Purchase Agreement described in Item 1.01 above, effective upon the closing of the initial tranche of the private placement, Mr. Bailey, as a current member of the Company’s Board of Directors (the “ Board ”), was appointed as Co-Chairman of the Board, to serve alongside the current Executive Chairman, Balkrishan “Simba” Gill.”
  3. Mar 19, 2026InsiderOfficer sold ~$98K of SER shares in the open market
  4. Mar 23, 2026InsiderOfficer sold ~$19K of SER shares in the open market
  5. Mar 25, 2026Company filing · Form 8-K · ResultsReported its results
  6. Apr 15, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year“On April 20, 2026, Serina Therapeutics (AL), Inc. (the “ Serina (AL) ”), a wholly owned subsidiary of Serina Therapeutics, Inc. (the “ Company ”), named Srini Tenjarla, Ph.D., its Chief Technology Officer.”
  7. May 14, 2026Company filing · Form 8-K · ResultsReported its results
  8. May 19, 2026Insider · First insider buy since Dec 2024Director purchased ~$20K of SER shares in the open market
  9. May 21, 2026Insider · Their first buy on recordDirector purchased ~$18K of SER shares in the open market
  10. May 22, 2026Insider · 3 insiders in a week, a first since 2018Director purchased ~$19K of SER shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Serina Therapeutics

OQRO holds no insider, Congress, fund or contract record for Serina Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SER page.

Other recent filings by Randall Moreadith, Chief Scientific Officer

The full history of Randall Moreadith, Chief Scientific Officer is on the profile page.

How this filing works

Other disclosures at Serina Therapeutics

Everything OQRO holds on this company is on its SER page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data